Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents
Date
2009-02Author
Boaz, Mark J.
Hayes, Peter
Tarragona, Tony
Seamons, Laura
Cooper, Andrew
Birungi, Josephine
Kitandwe, Paul
Semaganda, Aloysius
Kaleebu, Pontiano
Stevens, Gwynneth
Anzala, Omu
Farah, Bashir
Ogola, Simon
Indangasi, Jackton
Mhlanga, Patrick
Eeden, Melanie Van
Thakar, Madhuri
Pujari, Ashwini
Mishra, Shadri
Goonetilleke, Nilu
Moore, Stephen
Mahmoud, Abdul
Sathyamoorthy, Pattabiraman
Mahalingam, Jayashri
Narayanan, Paranji R.
Ramanathan, Vadakkuppattu D.
Cox, Josephine H.
Dally, Len
Gill, Dilbinder K.
Gilmour, Jill
Metadata
Show full item recordAbstract
The gamma interferon (IFN-_) enzyme-linked immunospot (ELISPOT) assay is used routinely to evaluate the potency of human immunodeficiency virus (HIV) vaccine candidates and other vaccine candidates. In order to compare candidates and pool data from multiple trial laboratories, validated standardized methods must be applied across laboratories. Proficiency panels are a key part of a comprehensive quality assurance program to monitor inter- and intralaboratory performance, as well as assay performance, over time. Seven International
AIDS Vaccine Initiative-sponsored trial sites participated in the proficiency panels described in this study. At each laboratory, two operators independently processed identical sample sets consisting of frozen peripheral blood mononuclear cell (PBMC) samples from different donors by using four blind stimuli. PBMCM recovery and viability after overnight resting and the IFN-_ ELISPOT assay performance were assessed. All sites demonstrated good performance in PBMC thawing and resting, with a median recovery of 78% and median viability of 95%. The laboratories were able to detect similar antigen-specific T-cell responses, ranging from 50 to >3,000 spot-forming cells per million PBMC. An approximate range of a half log in results from operators within or across sites was seen in comparisons of antigen-specific responses. Consistently low background responses were seen in all laboratories. The results of these proficiency panels demonstrate the ability of seven laboratories, located across three continents, to process PBMC samples and to rank volunteers with differential magnitudes of IFN-_ ELISPOT responses. These findings also illustrate the ability to standardize the IFN-_ ELISPOT assay across multiple laboratories when common training methods, reagents such as fetal calf serum, and standard operating procedures are adopted. These results are encouraging for laboratories that are using cell-based immunology assays to test HIV vaccines and other vaccines.
Use this URI to cite this item:
https://hdl.handle.net/20.500.11951/326Collections
- School of Medicine [158]